Ecopipam Does Not Adversely Affect Metabolic Parameters in Pediatric Patients With Tourette Syndrome (TS): Results From a Phase 2b Randomized, Placebo-Controlled Trial (RCT) With a 12-Month Open-Label Extension (OLE)

被引：0
|
作者：
Gilbert, D. L.
Atkinson, S. D.
Karkanias, G. B.
Munschauer, F.
Wanaski, S.
Cunniff, T.
机构：
来源：
ANNALS OF NEUROLOGY | 2025年 / 96卷
关键词：
Experimental Therapeutics; Movement Disorders;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
96
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
    Shapiro, Amy
    Castaman, Giancarlo
    Cepo, Katarina
    Poulsen, Lone Hvitfeldt
    Hollensen, Christian
    Matsushita, Tadashi
    Young, Guy
    Zupancic-Salek, Silva
    Jimenez-Yuste, Victor
    BLOOD, 2019, 134
  • [32] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, David W.
    Ailani, Jessica
    Goadsby, Peter J.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Li, Ye
    Szegedi, Armin
    CEPHALALGIA, 2019, 39 : 183 - 184
  • [33] Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
    Blauvelt, Andrew
    Papp, Kim A.
    Merola, Joseph F.
    Gottlieb, Alice B.
    Cross, Nancy
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1367 - 1374
  • [34] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, D. W.
    Ailani, J.
    Goadsby, P. J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Li, Y.
    Szegedi, A.
    HEADACHE, 2019, 59 : 79 - 80
  • [35] Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial
    Yang, Shenmiao
    Huang, Haiwen
    Zhou, Keshu
    Zhao, Xielan
    Han, Yanqiu
    Li, Lindong
    Butturini, Anna
    Wang, Yujie
    Liu, Xiaofeng
    Lai, Peiqiong
    Li, Jianyong
    BLOOD, 2023, 142
  • [36] Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan
    Nakaoka, Yoshikazu
    Isobe, Mitsuaki
    Takei, Syuji
    Tanaka, Yoshiya
    Ishii, Tomonori
    Yokota, Shumpei
    Nomura, Akira
    Yoshida, Seitaro
    Nishimoto, Norihiro
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer's Disease
    Viglietta, Vissia
    O'Gorman, John
    Williams, Leslie
    Chen, Tianle
    Enayetallah, Ahmed
    Chiao, Ping
    Hock, Christoph
    Nitsch, Roger
    Haeberlein, Samantha Budd
    Sandrock, Alfred
    NEUROLOGY, 2017, 88
  • [38] Efficacy and Tolerability of Intranasal Fentanyl Spray 50 to 200 μg for Breakthrough Pain in Patients With Cancer: A Phase III, Multinational, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial With a 10-Month, Open-Label Extension Treatment Period
    Kress, Hans Georg
    Oronska, Anna
    Kaczmarek, Zbigniew
    Kaasa, Stein
    Colberg, Torben
    Nolte, Thomas
    CLINICAL THERAPEUTICS, 2009, 31 (06) : 1177 - 1191
  • [39] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Dorner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W. L.
    Hueber, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 593 - 594
  • [40] Tenapanor's Sustained Response in Patients With Constipation Predominant Irritable Bowel Syndrome: Post-hoc Analysis From a 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial
    Chey, William D.
    Lembo, Anthony J.
    Rosenbaum, David P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S756 - S756
12345